Efficacy of osimertinib against EGFRvIII+ glioblastoma

Epidermal Growth Factor Receptor variant III (EGFRvIII) is an active mutant form of EGFR that drives tumor growth in a subset of glioblastoma (GBM). It occurs in over 20% of GBMs, making it a promising receptor for small molecule targeted therapy. We hypothesize that poor penetration of the blood-br...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Chagoya, Gustavo, Kwatra, Shawn G., Nanni, Cory W., Roberts, Callie M., Phillips, Samantha M., Nullmeyergh, Sarah, Gilmore, Samuel P., Spasojevic, Ivan, Corcoran, David L., Young, Christopher C., Ballman, Karla V., Ramakrishna, Rohan, Cross, Darren A., Markert, James M., Lim, Michael, Gilbert, Mark R., Lesser, Glenn J., Kwatra, Madan M.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2020
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7275784/
https://ncbi.nlm.nih.gov/pubmed/32547705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27599
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados